Treatment of hepatitis C in difficult-to-treat patients

Nature Reviews Gastroenterology and Hepatology

Volumn 12, Issue 5, 2015, Pages 284-292

  Ferenci, Peter ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ASUNAPREVIR; BECLABUVIR; BOCEPREVIR; DACLATASVIR; DASABUVIR; ELBASVIR; ERYTHROPOIETIN; GRAZOPREVIR; INTERFERON; LEDIPASVIR; OMBITASVIR; PARITAPREVIR; PEGINTERFERON; PROTEINASE INHIBITOR; RIBAVIRIN; RITONAVIR; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; ANTIVIRUS AGENT;

ADD ON THERAPY; ANEMIA; CHILD PUGH SCORE; DECOMPENSATED LIVER CIRRHOSIS; DIARRHEA; DIFFICULT TO TREAT PATIENT; DRUG CHOICE; DRUG COST; DRUG SAFETY; FATIGUE; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 3; HEPATITIS C VIRUS GENOTYPE 4; HUMAN; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; PATIENT; PRIORITY JOURNAL; REVIEW; TREATMENT DURATION; COMPLICATION; HEPATITIS C, CHRONIC; KIDNEY DISEASES;

ANTIVIRAL AGENTS; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; KIDNEY DISEASES; LIVER CIRRHOSIS; LIVER TRANSPLANTATION;

EID: 84929707044     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2015.53     Document Type: Review

References (90)

1. Thomas, D. L. Global control of hepatitis C: where challenge meets opportunity. Nat. Med. 19, 850-858 (2013).
2. Gower, E., Estes, C., Blach, S., Razavi-Shearer, K. & Razavi, H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J. Hepatol. 61 (Suppl. 1), S45-S57 (2014).
3. Ly, K. N. et al. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann. Intern. Med. 156, 271-278 (2012).
4. Hoofnagle, J. H. et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N. Engl. J. Med. 315, 1575-1578 (1986).
5. Jacobson, I. M. et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N. Engl. J. Med. 364, 2405-2416 (2011).
6. Poordad, F. et al. Boceprevir for untreated chronic HCV genotype 1 infection. N. Engl. J. Med. 364, 1207-1217 (2011).
7. McHutchison, J. G. et al. Telaprevir for previously treated chronic HCV infection. N. Engl. J. Med. 362, 1292-1303 (2010).
8. Bacon, B. R. et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N. Engl. J. Med. 364, 1207-1217 (2011).
9. Hezode, C. et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French early access program (ANRS CO20-CUPIC) - NCT01514890. J. Hepatol. 59, 434-441 (2013).
10. Gane, E. J. et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 376, 1467-1475 (2010).
11. Ferenci, P. Safety and efficacy of treatment for chronic hepatitis C with a focus on pegylated interferons: the backbone of therapy today and in the future. Expert Opin. Drug Saf. 10, 529-544 (2011).
12. Gordon, S. C. et al. Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET. J. Hepatol. 62, 286-293 (2015).
13. Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO clinical practice guidelines for the prevention, evaluation and treatment of hepatitis C in chronic kidney disease. Kidney Int. 73 (Suppl. 109), S1-S99 (2008).
14. Morales, J. M. & Fabrizi, F. Hepatitis C and its impact on renal transplantation. Nat. Rev. Nephrol. 11, 172-182 (2015).
15. Afdhal, N. et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N. Engl. J. Med. 370, 1889-1898 (2014).
16. Afdhal, N. et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N. Engl. J. Med. 370, 1483-1493 (2014).
17. Kowdley, K. V. et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N. Engl. J. Med. 370, 1879-1888 (2014).
18. Ferenci, P. et al. ABT-450/r-Ombitasvir-and dasabuvir with or without ribavirin for hepatitis C genotype 1. N. Engl. J. Med. 370, 1983-1992 (2014).
19. Andreone, P. et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology 147, 359-365 (2014).
20. Feld, J. J. et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N. Engl. J. Med. 370, 1594-1603 (2014).
21. Zeuzem, S. et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N. Engl. J. Med. 370, 1604-1614 (2014).
22. Chayama, K. et al. Randomized trial of interferon-and ribavirin-free ombitasvir/paritaprevir/ritonavir in treatment-experienced HCV-infected patients. Hepatology http://dx.doi.org/10.1002/hep.27705.
23. Friedman, S. L. Mechanisms of hepatic fibrogenesis. Gastroenterology 134, 1655-1669 (2008).
24. Poordad, F. et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N. Engl. J. Med. 370, 1973-1982 (2014).
25. Flamm, S. L. et al. Ledipasvir/sofosbuvir with ribavirin for the treatment of HCV in patients with decompensated cirrhosis: preliminary results of a prospective, multicenter study. Hepatology 60 (Suppl. 1), 320A (2014).
26. Bourliere, M. et al. An integrated safety and efficacy analysis of >500 patients with compensated cirrhosis treated with ledipasvir/sofosbuvir with or without ribavirin. Hepatology 60 (Suppl. 1), 239A (2014).
27. Fried, M. et al. TURQUOISE-II: regimens of abt-450/r/ombitasvir and dasabuvir with ribavirin achieve high SVR12 rates in HCV genotype 1-infected patients with cirrhosis, regardless of baseline characteristics. Hepatology 60 (Suppl. 1), 1145A (2014).
28. Bourliere, M. et al. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS) Lancet Infect. Dis. 15, 397-404 (2015).
29. Messina, J. P. et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 61, 77-87 (2015).
30. Zeuzem, S. et al. Sofosbuvir and ribavirin in HCV genotype 2 and 3. N. Engl. J. Med. 370, 1993-2001 (2014).
31. Nelson, D. et al. All-oral 12-week combination treatment with daclatasvir (DCV) and sofosbuvir (SOF) in patients infected with HCV genotype (GT) 3: ALLY-3 phase 3 study. Hepatology 61, 1127-1135 (2015).
32. Gane, E. et al. High efficacy of LDV/SOF regimens for 12 weeks for patients with HCV genotype 3 or 6 infection. Hepatology 60 (Suppl. 1), 1274A (2014).
33. Ruiz, I. et al. Patient with decompensated hepatitis C virus-related cirrhosis delisted for liver transplantation after successful sofosbuvir-based treatment. Liver Transpl. 21, 408-409 (2015).
34. Kozbial, K. et al. Early viral kinetics during interferon-free sofosbuvir containing treatment regimens in a real-life cohort of chronic hepatitis C Patients. Hepatology 60 (Suppl. 1), 701A (2014).
35. Welzel, T. M. et al. On-treatment HCV RNA as a predictor of virologic response in the ledipasvir/sofosbuvir phase 3 program for HCV genotype 1 infection: analysis of the ION-1, ION-2, and ION-3 Studies. Hepatology 60 (Suppl. 1), 1132A (2014).
36. Mandorfer, M. et al., Impaired early viral kinetics in patients with cirrhosis treated with interferon-free regimens-the impact of portal pressure. Hepatology 60 (Suppl. 1), 1152A (2014).
37. Ouwerkerk-Mahadevan, M. et al. Pharmacokinetics of simeprevir (TMC435) in volunteers with moderate or severe hepatic impairment. J. Hepatol. 58, S365 (2013).
38. Khatri, A. et al. Pharmacokinetics and safety of coadministered ABT-450 plus ritonavir(ABT-450/r), ABT-267 and ABT-333 as a single dose in subjects with normal hepatic function and in subjects with mild, moderate, and severe hepatic impairment. Hepatology 56 (Suppl. 1), 555A (2012).
39. Harvoni® (ledipasvir and sofosbuvir). Highlights of prescribing information [online], http://www.gilead.com/~/media/Files/pdfs/medicines/liver-disease/harvoni/harvoni-pi.pdf (2014).
40. de Kanter, C. T. et al. Viral hepatitis C therapy: pharmacokinetic and pharmacodynamic considerations. Clin. Pharmacokinet. 53, 409-427 (2014).
41. Copegus®(ribavirin). Highlights of prescribing information [online], http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/021511s023lbl.pdf (2011).
42. Muir, A. et al. All-oral fixed-dose combination therapy with daclatasvir/asunaprevir/beclabuvir, ± ribavirin, for patients with chronic HCV genotype 1 infection and compensated cirrhosis: UNITY-2 phase 3 SVR12 results. Hepatology 60, 1267A (2014).
43. Lenz, O. et al. Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies. J. Hepatol. http://dx.doi.org/10.1016/j.jhep.2014.11.032.
44. Poordad, F. et al. All-oral, fixed-dose combination therapy with daclatasvir/asunaprevir/BMS-791325 for non-cirrhotic patients with chronic HCV genotype 1 infection: UNITY-1 Phase 3 SVR12 results. Hepatology 60 (Suppl. 1), 1271A (2014).
45. Berenguer, M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J. Hepatol. 49, 274-287 (2008).
46. Burton, J. R. Jr et al. A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy. J. Hepatol. 61, 508-514 (2014).
47. Verna, E. C. et al. Telaprevir- and boceprevir-based triple therapy for hepatitis C in liver transplant recipients with advanced recurrent disease: a multicenter study. Transplantation http://dx.doi.org/10.1097/TP.0000000000000629.
48. Coilly, A. et al. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience. J. Hepatol. 60, 78-86 (2014).
49. Pungpapong, S. et al. Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation. Liver Transpl. 19, 690-700 (2013).
50. Verna, E. C. et al. High post-transplant virological response in hepatitis C virus infected patients treated with pretransplant protease inhibitor-based triple therapy. Liver Int. 35, 510-517 (2015).
51. Kwo, P. Y. et al. An interferon-free antiviral regimen for HCV after liver transplantation. N. Engl. J. Med. 371, 2375-2382 (2014).
52. Charlton, M. et al. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology 148, 108-117 (2015).
53. Forns, X. et al. Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C following liver transplantation. Hepatology http://dx.doi.org/10.1002/hep.27681.
54. Pungpapong, S. et al. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant. Hepatology http://dx.doi.org/10.1002/hep.27770.
55. Curry, M. P. et al. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study. Gastroenterology 148, 100-107 (2015).
56. Reddy, R. et al. Ledipasvir/sofosbuvir with ribavirin for the treatment of HCV in Patients with post transplant recurrence: preliminary results of a prospective, multicenter study. Hepatology 60 (Suppl. 1), 200A (2014).
57. Ruiz, I. et al. Patient with decompensated hepatitis C virus-related cirrhosis delisted for liver transplantation after successful sofosbuvir-based treatment. Liver Transpl. http://dx.doi.org/10.1002/lt.24051.
58. German, P. et al. Drug-drug interaction profile of the fixed-dose combination tablet ledipasvir/sofosbuvir. Hepatology 60 (Suppl. 1), 1162A (2014).
59. Badri, P. et al. Pharmacokinetics of cyclosporine and tacrolimus, following coadministration with the direct acting antiviral combination, ABT-450/r, ombitasvir and dasabuvir, in liver transplant patients with genotype-1 HCV infection. Hepatology 60 (Suppl. 1), 1141A (2014).
60. Mathurin, P. et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology 29, 257-263 (1999).
61. Lee, J. J. et al. Hepatitis C virus infection increases risk of developing end-stage renal disease using competing risk analysis. PLoS ONE 9, e100790 (2014).
62. Gane, E. et al. Safety, anti-viral efficacy and pharmacokinetics (PK) of sofosbuvir (SOF) in patients with severe renal impairment. Hepatology 60 (Suppl. 1), 667A (2014).
63. Bhamidimarri, K. R. et al. Urgent treatment with sofosbuvir based regimen for. hepatitis C Genotype 1 patients with severe renal insufficiency (GFR <30ml/min). Hepatology 60 (Suppl. 1), 545A (2014).
64. Khatri, A. et al. The pharmacokinetics and safety of the direct acting antiviral regimen of ABT-450/r, ombitasvir with/without dasabuvir in subjects with mild, moderate and severe renal impairment compared to subjects with normal renal function. Hepatology 60 (Suppl. 1), 320A (2014).
65. Lawitz, E. et al. Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis. Hepatology 61, 769-775 (2015).
66. Donaldson, E. F. et al. Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir. Hepatology 61, 56-65 (2015).
67. Wyle, D. et al. Retreatment of patients who failed prior sofosbuvir-based regimens with all oral fixed-dose combination ledipasvir/sofosbuvir plus ribavirin for 12 weeks. Hepatology 60 (Suppl. 1), 317A (2014).
68. Lawitz, E. et al. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. Lancet 385, 1075-1086 (2015).
69. Everson, G. T. et al. Efficacy of an interferon-and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection. Gastroenterology 146, 420-429 (2014).
70. Muir, A. et al. All-oral fixed-dose combination therapy with daclatasvir/asunaprevir/beclabuvir, ± ribavirin, for patients with chronic HCV genotype 1 infection and compensated cirrhosis: unity-2 phase 3 SVR12 results. Hepatology 60, 1267A (2014).
71. Lawitz, E. et al. C-SWIFT: MK-5172 + MK-8742 + Sofosbuvir in treatment-naive patients with hepatitis C virus genotype 1 infection, with and without cirrhosis, for durations of 4, 6, or 8 weeks. Hepatology 60 (Suppl. 1), 1286A (2014).
72. van der Meer, A. J. et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 308, 2584-2593 (2012).
73. Rutter, K. et al. Successful antiviral treatment improves survival of patients with advanced liver disease due to chronic hepatitis C. Aliment. Pharmacol. Ther. 41, 521-531 (2015).
74. van der Meer, A. J. et al. Life expectancy in patients with chronic HCV infection and cirrhosis compared with a general population. JAMA 312, 1927-1928 (2014).
75. Kielland, K. B. et al. All-cause and liver-related mortality in hepatitis C infected drug users followed for 33 years: a controlled study. J. Hepatol. 58, 31-37 (2013).
76. Lutchman, G. & Kim, R. A. Glass half full: implications of screening for HCV in the era of highly effective antiviral therapy. Hepatology http://dx.doi.org/10.1002/hep.27718.
77. American Association for the Study of Liver Diseases & Infectious Diseases Society of America. Recommendations for testing, managing, and treating hepatitis C [online], http://www.hcvguidelines.org (2014).
78. European Association for Study of Liver. EASL clinical practice guidelines: management of hepatitis C virus infection. J. Hepatol. 60, 392-420 (2014).
79. Reau, N. S. & Jensen, D. M. Sticker shock and the price of new therapies for hepatitis C: is it worth it? Hepatology 59, 1246-1249 (2014).
80. Sidharthan, S. et al. Utility of hepatitis C viral load monitoring on directly acting antiviral therapy. Clin. Infect. Dis. http://dx.doi.org/10.1093/cid/civ170.
81. Vermehren, J. et al. Clinical significance of residual viremia detected by two real-time PCR assays for response-guided therapy of HCV genotype 1 infection. J. Hepatol. 60, 913-919 (2014).
82. Sarrazin, C. et al. Importance of very early HCV RNA kinetics for prediction of treatment outcome of highly effective all oral direct acting antiviral combination therapy. J. Virol. Methods 214, 29-32 (2015).
83. Brown, R. S. et al. Safety and efficacy of new DAA-based therapy for hepatitis C post-transplant: interval results from the HCV-TARGET longitudinal, observational study. Hepatology 60, 1269A (2014).
84. Punzalan, P. S. et al. Successful treatment of post liver transplant patients with genotype 1 hepatitis C virus with sofosbuvir and simeprevir. Hepatology 60 (Suppl. 1), 688A (2014).
85. Ford, R. M. et al. Post-liver transplant treatment of hepatitis C with a combination of sofosbuvir, simeprevir ± ribavirin at a high volume academic transplant center. Hepatology 60 (Suppl. 1), 701A (2014).
86. Fontana, R. et al. High efficacy and favorable safety profile of daclatasvir based all oral antiviral therapy in liver transplant recipients with severe recurrent HCV. Hepatology 60, 1280A (2014).
87. Leroy, V. et al. High rates of virological response and major clinical improvement during sofosbuvir and daclatasvir-based regimens for the treatment of fibrosing cholestatic HCV-recurrence after liver transplantation: The ANRS CO23 CUPILT Study. Hepatology 60 (Suppl. 1), 207A (2014).
88. Vukotic, R. et al. Sofobuvir for severe HCV recurrence post-transplant: AISF-SOFOLT Italian Compassionate Use. Hepatology 60 (Suppl. 1), 1273A (2014).
89. Gordon, F. et al. Sofosbuvir + simeprevir is safe in liver transplant recipients. Hepatology 60 (Suppl. 1), 543A (2014).
90. Crittenden, N. et al. Single center experience with simeprevir/sofosbuvir combination therapy for recurrent hepatitis C virus infection in liver transplant recipients. Hepatology 60 (Suppl. 1), 700A (2014).